Disease progression and the application of evidence-based treatment guidelines diagnose it early: a case for screening and appropriate management.
BACKGROUND
Screening processes to identify patients who have chronic kidney disease (CKD) early in the disease allow time to manage its comorbidities and complications effectively and aggressively. The Kidney Early Evaluation Program (KEEP), sponsored by the National Kidney Foundation (NKF), is a free screening program that targets people who have diabetes, hypertension, and parents, grandparents, or siblings with diabetes, hypertension, or CKD.


OBJECTIVE
To (1) introduce KEEP and its objectives and (2) review population data and progress with goals to date.


CONCLUSIONS
The KEEP goals are to raise awareness of CKD, especially in high-risk patients, provide free testing, and encourage dialogue between patients and their physicians, leading to a treatment plan. Of the 55,000 patients who have been screened through KEEP, approximately 13,000 (29%), or nearly 1 in 3 patients, have been identified as having CKD. Once a patient has been diagnosed with CKD, clinicians must address risk factors such as diabetes, hypertension, and kidney-specific diseases (e.g., glomerular diseases) that contribute to the process of renal decline. The NKF through the Kidney Disease Outcomes Quality Initiative has assembled a series of guidelines addressing dialysis adequacy, vascular access, anemia, nutrition, CKD, bone and mineral metabolism, dyslipidemia, hypertension, cardiovascular disease, and diabetes.


CONCLUSIONS
CKD is quite common but often unrecognized and undertreated, even though rigorous guidelines for diagnosis and care have been developed. Ten areas have been identified as important for optimal care of the CKD patient. Each of these areas should be addressed and closely monitored in this population: hypertension, anemia, glucose control, lipid control, smoking cessation, aspirin prophylaxis and use of a beta-blocker post-myocardial infarction, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, diet, exercise, and weight control.
Manley
Harold J
HJ
VillageHealth Disease Management, Glenmont, NY 12077, USA. harold.manley@villagehealth.com
D018450:Disease Progression; D042241:Early Diagnosis; D019317:Evidence-Based Medicine / Q000379:methods* / Q000592:standards; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis* / Q000628:therapy*; D008403:Mass Screening / Q000379:methods / Q000458:organization & administration; D017410:Practice Guidelines as Topic / Q000592:standards*; D012307:Risk Factors